clinical trial Archives | Be Korea-savvy
TrialScope Atlas Helps Sponsors Reduce Risk, Manage the Complicated Global Clinical Trial Disclosure Process

TrialScope Atlas Helps Sponsors Reduce Risk, Manage the Complicated Global Clinical Trial Disclosure Process

NEW YORK, Oct. 26 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, has launched TrialScope Atlas, a single, searchable dashboard that automates clinical trial disclosure and consolidates a concise set of relevant regulations. Clinical trial sponsors are under increased pressure to maintain regulatory disclosure compliance, for several reasons: The EU [...]

Covicept Therapeutics Initiates a Phase 2 Clinical Study with PJS-539, an Oral Small Molecule for the Treatment of Patients with COVID-19 (SARS-CoV-2)

Covicept Therapeutics Initiates a Phase 2 Clinical Study with PJS-539, an Oral Small Molecule for the Treatment of Patients with COVID-19 (SARS-CoV-2)

San Diego, USA, Oct. 6 (Korea Bizwire) – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19. PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential [...]

Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 16 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line [...]

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

WALTHAM, Mass., Sept. 10 (Korea Bizwire) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a [...]

TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

EDMONTON, Alberta, Aug. 31 (Korea Bizwire) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label global clinical trial of adjuvant endocrine therapy, giredestrant (GDC-9545) sponsored by F. Hoffmann-LaRoche. Giredestrant is an oral selective [...]

SK Bioscience Kicks Off Phase 3 Clinical Trial of its COVID-19 Vaccine Candidate

SK Bioscience Kicks Off Phase 3 Clinical Trial of its COVID-19 Vaccine Candidate

SEOUL, Aug. 30 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Monday it has begun the phase three clinical trial of its COVID-19 vaccine candidate. GBP510, under development by SK Bioscience, a unit of the country’s No. 2 family-controlled conglomerate SK Group, was administered to the first participant. It comes nearly three weeks [...]

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

SHANGHAI, China, and REDWOOD CITY, Calif., Aug. 18 (Korea Bizwire) —  Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or [...]

Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment

Patients Rate their Clinical Trial Experience Positively, but Trial Locations Still Pose Barriers to Enrollment

NEW YORK, July 27 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, released its first “Patient Perspectives on Clinical Trial Participation” report, which measured patient attitudes in relation to all stages of the clinical trial process following the onset of the COVID-19 pandemic. The study, conducted online in partnership [...]

Informa Pharma Intelligence Launches Citeline Study Feasibility to Accelerate Clinical Trial Timelines

Informa Pharma Intelligence Launches Citeline Study Feasibility to Accelerate Clinical Trial Timelines

NEW YORK, June 16 (Korea Bizwire) – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, today announced the launch of Citeline Study Feasibility – an AI-driven platform that delivers predictive analytics to improve clinical trial decisions and cycle times. By combining its best-in-class data sets with machine learning capabilities, this solution will [...]

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

BARCELONA, Spain, May 6 (Korea Bizwire) — Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase [...]